APCCC 2022 | Subgroups of metastatic hormone-sensitive prostate cancer (mHSPC)

Silke Gillessen, MD, PhD, University of Lugano, Lugano, Switzerland and the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, discusses metastatic hormone-sensitive prostate cancer (mHSPC). Prof. Gillessen describes how mHSPC is currently divided into four main subgroups based on clinical factors (de novo disease compared to relapsed disease), as well as the distinction between low-volume and high-volume metastatic disease. Prof. Gillessen also discusses the differences in the prognoses of the mHSPC subgroups. This interview took place at the APCCC 2022 conference, held in Lugano, Switzerland.